Altimmune, Inc. (ALT)
Altimmune, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Altimmune, Inc. (ALT) is a Biotechnology company based in US with a market capitalization of $248.9M. Revenue grew 105.0% year-over-year and free cash flow was negative at -$67.5M. This page tracks ALT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 59 employees · IPO May 26, 2017
Valuation
Valuation & price
$2.85as of May 17, 2026· -53.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.11
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$248.9M
Market cap
105.0%
Revenue growth (YoY)
100.0%
Gross margin
-$67.5M
Free cash flow (USD)
-$237.8M
Net debt
Net cash position
24.1%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 16, 2026Filing
Headquarters Relocation
- 8-K eventMay 13, 2026Filing
Earnings Release
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- 8-K eventApr 24, 2026Filing
Stock Offering
- 8-K eventApr 16, 2026Filing
Authorized Shares Increase
- Insider buyApr 6, 2026Filing
Insider Buy $31KGILL JOHN · Director · $31.3K
- Insider buyApr 1, 2026Filing
Insider Buy $47KDurso Jerome Benedict · Director, President and CEO · $47.1K
- Insider buyApr 1, 2026Filing
Insider Buy $31KWEAVER GREGORY L · Chief Financial Officer · $31.5K
Questions
Frequently asked questions
What is Altimmune, Inc.'s market cap?
Altimmune, Inc. (ALT) has a market capitalization of $248.9M.
What is ALT's P/E ratio?
A meaningful P/E ratio is not available for ALT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ALT's price-to-book (P/B) ratio?
ALT trades at 1.11 times book value per share.
Are insiders buying ALT stock?
SEC Form 4 filings show no open-market insider buys at Altimmune, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.